Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRUGLESS-CRT: Withdrawal of Heart Failure Treatment in Super-responders to CRT
NCT07851779Phase 4Recruiting
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in Non-Ischaemic Cardiomyopathy (NICM) (2 arms), sponsored by Bellvitge Institute for Biomedical Research. Primary endpoint: Recurrence of left ventricular dysfunction or heart failure symptoms at 6 months. Started Jan 2026; status: recruiting.
02
Conditions
Non-Ischaemic Cardiomyopathy (NICM)
Beyond the preview
Go deeper on NCT07851779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07851779.